Medication adherence and growth in children with CKD

Oleh M. Akchurin, Michael F. Schneider, Lucy Mulqueen, Ellen R. Brooks, Craig B. Langman, Larry A. Greenbaum, Susan L. Furth, Marva Moxey-Mims, Bradley A. Warady, Frederick J. Kaskel, Amy L. Skversky

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and objectives: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. Design, setting, participants, & measurements: The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitaminD, nutritional vitaminD, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to eachmedication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. Results: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGHhad no change in height z score,whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. Conclusions: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.

Original languageEnglish (US)
Pages (from-to)1519-1525
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume9
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Medication Adherence
Human Growth Hormone
Growth Hormone
Social Adjustment
Growth
Linear Models
Erythrocytes
Confidence Intervals
Alkalies
Chronic Renal Insufficiency
Vitamin D
Prescriptions
Cohort Studies
Iron
Phosphates

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Akchurin, O. M., Schneider, M. F., Mulqueen, L., Brooks, E. R., Langman, C. B., Greenbaum, L. A., ... Skversky, A. L. (2014). Medication adherence and growth in children with CKD. Clinical Journal of the American Society of Nephrology, 9(9), 1519-1525. https://doi.org/10.2215/CJN.01150114

Medication adherence and growth in children with CKD. / Akchurin, Oleh M.; Schneider, Michael F.; Mulqueen, Lucy; Brooks, Ellen R.; Langman, Craig B.; Greenbaum, Larry A.; Furth, Susan L.; Moxey-Mims, Marva; Warady, Bradley A.; Kaskel, Frederick J.; Skversky, Amy L.

In: Clinical Journal of the American Society of Nephrology, Vol. 9, No. 9, 2014, p. 1519-1525.

Research output: Contribution to journalArticle

Akchurin, OM, Schneider, MF, Mulqueen, L, Brooks, ER, Langman, CB, Greenbaum, LA, Furth, SL, Moxey-Mims, M, Warady, BA, Kaskel, FJ & Skversky, AL 2014, 'Medication adherence and growth in children with CKD', Clinical Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1519-1525. https://doi.org/10.2215/CJN.01150114
Akchurin OM, Schneider MF, Mulqueen L, Brooks ER, Langman CB, Greenbaum LA et al. Medication adherence and growth in children with CKD. Clinical Journal of the American Society of Nephrology. 2014;9(9):1519-1525. https://doi.org/10.2215/CJN.01150114
Akchurin, Oleh M. ; Schneider, Michael F. ; Mulqueen, Lucy ; Brooks, Ellen R. ; Langman, Craig B. ; Greenbaum, Larry A. ; Furth, Susan L. ; Moxey-Mims, Marva ; Warady, Bradley A. ; Kaskel, Frederick J. ; Skversky, Amy L. / Medication adherence and growth in children with CKD. In: Clinical Journal of the American Society of Nephrology. 2014 ; Vol. 9, No. 9. pp. 1519-1525.
@article{a8911644aa374c0e83d6ffd8dc6b6645,
title = "Medication adherence and growth in children with CKD",
abstract = "Background and objectives: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. Design, setting, participants, & measurements: The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitaminD, nutritional vitaminD, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to eachmedication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. Results: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4{\%} over all visits for erythrocyte-stimulating agents to 22{\%} over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGHhad no change in height z score,whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95{\%} confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95{\%} confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. Conclusions: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.",
author = "Akchurin, {Oleh M.} and Schneider, {Michael F.} and Lucy Mulqueen and Brooks, {Ellen R.} and Langman, {Craig B.} and Greenbaum, {Larry A.} and Furth, {Susan L.} and Marva Moxey-Mims and Warady, {Bradley A.} and Kaskel, {Frederick J.} and Skversky, {Amy L.}",
year = "2014",
doi = "10.2215/CJN.01150114",
language = "English (US)",
volume = "9",
pages = "1519--1525",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Medication adherence and growth in children with CKD

AU - Akchurin, Oleh M.

AU - Schneider, Michael F.

AU - Mulqueen, Lucy

AU - Brooks, Ellen R.

AU - Langman, Craig B.

AU - Greenbaum, Larry A.

AU - Furth, Susan L.

AU - Moxey-Mims, Marva

AU - Warady, Bradley A.

AU - Kaskel, Frederick J.

AU - Skversky, Amy L.

PY - 2014

Y1 - 2014

N2 - Background and objectives: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. Design, setting, participants, & measurements: The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitaminD, nutritional vitaminD, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to eachmedication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. Results: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGHhad no change in height z score,whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. Conclusions: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.

AB - Background and objectives: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. Design, setting, participants, & measurements: The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitaminD, nutritional vitaminD, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to eachmedication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. Results: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGHhad no change in height z score,whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. Conclusions: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.

UR - http://www.scopus.com/inward/record.url?scp=84923788273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923788273&partnerID=8YFLogxK

U2 - 10.2215/CJN.01150114

DO - 10.2215/CJN.01150114

M3 - Article

C2 - 24970873

AN - SCOPUS:84923788273

VL - 9

SP - 1519

EP - 1525

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 9

ER -